A last-minute announcement from BionTech for the Delta variant would have allayed some of the concerns.
As vaccination campaigns continue at full speed around the world, Kovid-19 variants, which have started to appear in many countries, continue to cause concern. Uğur Şahin’s latest statement about the Delta variant, which has also been warned by the WHO that it has become dominant, was heartbreaking. Şahin said the BioNTech vaccine is effective against the variant and said that at this time we do not see the need to adapt the vaccine.
“The first generation Covid-19 vaccine developed by BioNTech-Pfizer is effective against all variants currently in circulation, including Delta. For this reason, we are not considering any adaptation studies of our vaccine at this time.
These words were spoken by the CEO of BionTech and head of the team that created the vaccine, Prof. Dr. It belongs to Uğur Şahin. Şahin breathed a sigh of relief around the world, saying it was not yet necessary to adapt the vaccine against the variants, in a statement he made today.
class = “cf”>
“Over the next 12 months, if new variants emerge, it may be possible to adapt the vaccine to those variants, but we don’t need them at this time.” Şahin said this can only be done if the vaccine is ineffective against the variants and this is proven by experiments and field data.
Stating that the formation of variants in the coronavirus outbreak and rapidly changing data make the question of timing very important, Şahin stressed that a hasty decision can lead to poor results.
“If a new variant emerges and becomes dominant in the next three or six months, the change we are making now will be to our detriment. It is therefore essential to make a very good assessment before making a decision. used his words.
Şahin continued his words as follows:
“Currently we have very healthy data for the third booster dose. The first generation primary vaccine has very high efficacy against the variants. We will proceed in light of this data.”
While stressing that the booster dose of the vaccine they developed with BionTech and Pfizer is preventing further waves from forming, countries like France and Germany have announced that they will recommend a third dose for their citizens in the group. elderly and at-risk people, and their schedules for it.
class = “cf”>
BioNTech-Pfizer has so far supplied more than one billion doses of vaccine to more than 100 countries. The company aims to increase its capacity to 3 billion doses by the end of the year. It has been announced that the target dose for 2022 will be 4 billion per year.